                         SEQUENCE LISTING

<110>  KAWAKAMI, Koji
       KOHNO, Masayuki
       HORIBE, Tomohisa
       NAKAJIMA, Oumi
       HARAMOTO, Mari
       YANG, Liying
 
<120>  Selective anticancer chimeric peptides

<130>  UPI001PCT

<150>  JP 2008-309176
<151>  2008-12-03

<150>  JP 2009-138729
<151>  2009-06-09

<160>  59    

<170>  PatentIn version 3.3

<210>  1
<211>  17
<212>  PRT
<213>  artificial sequence

<220>
<223>  cell membrane lytic peptide; position 3, 6, 8, 9 and 13 are 
       D-amino acids.

<400>  1

Lys Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys 
1               5                   10                  15      


Lys 
    


<210>  2
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  EB-lytic chimeric peptide; position 18, 21, 23, 24 and 28 are 
       D-amino acids.

<400>  2

Tyr His Trp Tyr Gly Tyr Thr Pro Gln Asn Val Ile Gly Gly Gly Lys 
1               5                   10                  15      


Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys Lys 
            20                  25                  30          


<210>  3
<211>  1186
<212>  PRT
<213>  artificial sequence

<220>
<223>  rhEGFR

<400>  3

Leu Glu Glu Lys Lys Val Cys Gln Gly Thr Ser Asn Lys Leu Thr Gln 
1               5                   10                  15      


Leu Gly Thr Phe Glu Asp His Phe Leu Ser Leu Gln Arg Met Phe Asn 
            20                  25                  30          


Asn Cys Glu Val Val Leu Gly Asn Leu Glu Ile Thr Tyr Val Gln Arg 
        35                  40                  45              


Asn Tyr Asp Leu Ser Phe Leu Lys Thr Ile Gln Glu Val Ala Gly Tyr 
    50                  55                  60                  


Val Leu Ile Ala Leu Asn Thr Val Glu Arg Ile Pro Leu Glu Asn Leu 
65                  70                  75                  80  


Gln Ile Ile Arg Gly Asn Met Tyr Tyr Glu Asn Ser Tyr Ala Leu Ala 
                85                  90                  95      


Val Leu Ser Asn Tyr Asp Ala Asn Lys Thr Gly Leu Lys Glu Leu Pro 
            100                 105                 110         


Met Arg Asn Leu Gln Glu Ile Leu His Gly Ala Val Arg Phe Ser Asn 
        115                 120                 125             


Asn Pro Ala Leu Cys Asn Val Glu Ser Ile Gln Trp Arg Asp Ile Val 
    130                 135                 140                 


Ser Ser Asp Phe Leu Ser Asn Met Ser Met Asp Phe Gln Asn His Leu 
145                 150                 155                 160 


Gly Ser Cys Gln Lys Cys Asp Pro Ser Cys Pro Asn Gly Ser Cys Trp 
                165                 170                 175     


Gly Ala Gly Glu Glu Asn Cys Gln Lys Leu Thr Lys Ile Ile Cys Ala 
            180                 185                 190         


Gln Gln Cys Ser Gly Arg Cys Arg Gly Lys Ser Pro Ser Asp Cys Cys 
        195                 200                 205             


His Asn Gln Cys Ala Ala Gly Cys Thr Gly Pro Arg Glu Ser Asp Cys 
    210                 215                 220                 


Leu Val Cys Arg Lys Phe Arg Asp Glu Ala Thr Cys Lys Asp Thr Cys 
225                 230                 235                 240 


Pro Pro Leu Met Leu Tyr Asn Pro Thr Thr Tyr Gln Met Asp Val Asn 
                245                 250                 255     


Pro Glu Gly Lys Tyr Ser Phe Gly Ala Thr Cys Val Lys Lys Cys Pro 
            260                 265                 270         


Arg Asn Tyr Val Val Thr Asp His Gly Ser Cys Val Arg Ala Cys Gly 
        275                 280                 285             


Ala Asp Ser Tyr Glu Met Glu Glu Asp Gly Val Arg Lys Cys Lys Lys 
    290                 295                 300                 


Cys Glu Gly Pro Cys Arg Lys Val Cys Asn Gly Ile Gly Ile Gly Glu 
305                 310                 315                 320 


Phe Lys Asp Ser Leu Ser Ile Asn Ala Thr Asn Ile Lys His Phe Lys 
                325                 330                 335     


Asn Cys Thr Ser Ile Ser Gly Asp Leu His Ile Leu Pro Val Ala Phe 
            340                 345                 350         


Arg Gly Asp Ser Phe Thr His Thr Pro Pro Leu Asp Pro Gln Glu Leu 
        355                 360                 365             


Asp Ile Leu Lys Thr Val Lys Glu Ile Thr Gly Phe Leu Leu Ile Gln 
    370                 375                 380                 


Ala Trp Pro Glu Asn Arg Thr Asp Leu His Ala Phe Glu Asn Leu Glu 
385                 390                 395                 400 


Ile Ile Arg Gly Arg Thr Lys Gln His Gly Gln Phe Ser Leu Ala Val 
                405                 410                 415     


Val Ser Leu Asn Ile Thr Ser Leu Gly Leu Arg Ser Leu Lys Glu Ile 
            420                 425                 430         


Ser Asp Gly Asp Val Ile Ile Ser Gly Asn Lys Asn Leu Cys Tyr Ala 
        435                 440                 445             


Asn Thr Ile Asn Trp Lys Lys Leu Phe Gly Thr Ser Gly Gln Lys Thr 
    450                 455                 460                 


Lys Ile Ile Ser Asn Arg Gly Glu Asn Ser Cys Lys Ala Thr Gly Gln 
465                 470                 475                 480 


Val Cys His Ala Leu Cys Ser Pro Glu Gly Cys Trp Gly Pro Glu Pro 
                485                 490                 495     


Arg Asp Cys Val Ser Cys Arg Asn Val Ser Arg Gly Arg Glu Cys Val 
            500                 505                 510         


Asp Lys Cys Asn Leu Leu Glu Gly Glu Pro Arg Glu Phe Val Glu Asn 
        515                 520                 525             


Ser Glu Cys Ile Gln Cys His Pro Glu Cys Leu Pro Gln Ala Met Asn 
    530                 535                 540                 


Ile Thr Cys Thr Gly Arg Gly Pro Asp Asn Cys Ile Gln Cys Ala His 
545                 550                 555                 560 


Tyr Ile Asp Gly Pro His Cys Val Lys Thr Cys Pro Ala Gly Val Met 
                565                 570                 575     


Gly Glu Asn Asn Thr Leu Val Trp Lys Tyr Ala Asp Ala Gly His Val 
            580                 585                 590         


Cys His Leu Cys His Pro Asn Cys Thr Tyr Gly Cys Thr Gly Pro Gly 
        595                 600                 605             


Leu Glu Gly Cys Pro Thr Asn Gly Pro Lys Ile Pro Ser Ile Ala Thr 
    610                 615                 620                 


Gly Met Val Gly Ala Leu Leu Leu Leu Leu Val Val Ala Leu Gly Ile 
625                 630                 635                 640 


Gly Leu Phe Met Arg Arg Arg His Ile Val Arg Lys Arg Thr Leu Arg 
                645                 650                 655     


Arg Leu Leu Gln Glu Arg Glu Leu Val Glu Pro Leu Thr Pro Ser Gly 
            660                 665                 670         


Glu Ala Pro Asn Gln Ala Leu Leu Arg Ile Leu Lys Glu Thr Glu Phe 
        675                 680                 685             


Lys Lys Ile Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys 
    690                 695                 700                 


Gly Leu Trp Ile Pro Glu Gly Glu Lys Val Lys Ile Pro Val Ala Ile 
705                 710                 715                 720 


Lys Glu Leu Arg Glu Ala Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu 
                725                 730                 735     


Asp Glu Ala Tyr Val Met Ala Ser Val Asp Asn Pro His Val Cys Arg 
            740                 745                 750         


Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Ile Thr Gln Leu 
        755                 760                 765             


Met Pro Phe Gly Cys Leu Leu Asp Tyr Val Arg Glu His Lys Asp Asn 
    770                 775                 780                 


Ile Gly Ser Gln Tyr Leu Leu Asn Trp Cys Val Gln Ile Ala Lys Gly 
785                 790                 795                 800 


Met Asn Tyr Leu Glu Asp Arg Arg Leu Val His Arg Asp Leu Ala Ala 
                805                 810                 815     


Arg Asn Val Leu Val Lys Thr Pro Gln His Val Lys Ile Thr Asp Phe 
            820                 825                 830         


Gly Leu Ala Lys Leu Leu Gly Ala Glu Glu Lys Glu Tyr His Ala Glu 
        835                 840                 845             


Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu His 
    850                 855                 860                 


Arg Ile Tyr Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val 
865                 870                 875                 880 


Trp Glu Leu Met Thr Phe Gly Ser Lys Pro Tyr Asp Gly Ile Pro Ala 
                885                 890                 895     


Ser Glu Ile Ser Ser Ile Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro 
            900                 905                 910         


Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met 
        915                 920                 925             


Ile Asp Ala Asp Ser Arg Pro Lys Phe Arg Glu Leu Ile Ile Glu Phe 
    930                 935                 940                 


Ser Lys Met Ala Arg Asp Pro Gln Arg Tyr Leu Val Ile Gln Gly Asp 
945                 950                 955                 960 


Glu Arg Met His Leu Pro Ser Pro Thr Asp Ser Asn Phe Tyr Arg Ala 
                965                 970                 975     


Leu Met Asp Glu Glu Asp Met Asp Asp Val Val Asp Ala Asp Glu Tyr 
            980                 985                 990         


Leu Ile Pro Gln Gln Gly Phe Phe  Ser Ser Pro Ser Thr  Ser Arg Thr 
        995                 1000                 1005             


Pro Leu  Leu Ser Ser Leu Ser  Ala Thr Ser Asn Asn  Ser Thr Val 
    1010                 1015                 1020             


Ala Cys  Ile Asp Arg Asn Gly  Leu Gln Ser Cys Pro  Ile Lys Glu 
    1025                 1030                 1035             


Asp Ser  Phe Leu Gln Arg Tyr  Ser Ser Asp Pro Thr  Gly Ala Leu 
    1040                 1045                 1050             


Thr Glu  Asp Ser Ile Asp Asp  Thr Phe Leu Pro Val  Pro Glu Tyr 
    1055                 1060                 1065             


Ile Asn  Gln Ser Val Pro Lys  Arg Pro Ala Gly Ser  Val Gln Asn 
    1070                 1075                 1080             


Pro Val  Tyr His Asn Gln Pro  Leu Asn Pro Ala Pro  Ser Arg Asp 
    1085                 1090                 1095             


Pro His  Tyr Gln Asp Pro His  Ser Thr Ala Val Gly  Asn Pro Glu 
    1100                 1105                 1110             


Tyr Leu  Asn Thr Val Gln Pro  Thr Cys Val Asn Ser  Thr Phe Asp 
    1115                 1120                 1125             


Ser Pro  Ala His Trp Ala Gln  Lys Gly Ser His Gln  Ile Ser Leu 
    1130                 1135                 1140             


Asp Asn  Pro Asp Tyr Gln Gln  Asp Phe Phe Pro Lys  Glu Ala Lys 
    1145                 1150                 1155             


Pro Asn  Gly Ile Phe Lys Gly  Ser Thr Ala Glu Asn  Ala Glu Tyr 
    1160                 1165                 1170             


Leu Arg  Val Ala Pro Gln Ser  Ser Glu Phe Ile Gly  Ala 
    1175                 1180                 1185     


<210>  4
<211>  14
<212>  PRT
<213>  artificial sequence

<220>
<223>  polycationinc sequence

<400>  4

Lys Leu Ala Lys Leu Ala Lys Lys Leu Ala Lys Leu Ala Lys 
1               5                   10                  


<210>  5
<211>  7
<212>  PRT
<213>  artificial sequence

<220>
<223>  FGFR binding peptide

<400>  5

Met Gln Leu Pro Leu Ala Thr 
1               5           


<210>  6
<211>  16
<212>  PRT
<213>  artificial sequence

<220>
<223>  FGFR binding peptide

<400>  6

Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro 
1               5                   10                  15      


<210>  7
<211>  12
<212>  PRT
<213>  artificial sequence

<220>
<223>  EGFR binding peptide

<400>  7

Tyr His Trp Tyr Gly Tyr Thr Pro Gln Asn Val Ile 
1               5                   10          


<210>  8
<211>  12
<212>  PRT
<213>  artificial sequence

<220>
<223>  EGFR binding peptide analog


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa corresponds to X1 as defined in the specification

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Xaa corresponds to X2 as defined in the specification

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa corresponds to X3 as defined in the specification

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  Xaa corresponds to X4 as defined in the specification

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  Xaa corresponds to X5 as defined in the specification

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  Xaa corresponds to X6 as defined in the specification

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa corresponds to X7 as defined in the specification

<220>
<221>  misc_feature
<222>  (8)..(8)
<223>  Xaa corresponds to X8 as defined in the specification

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  Xaa corresponds to X9 as defined in the specification

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa corresponds to X10 as defined in the specification

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa corresponds to X11 as defined in the specification

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  Xaa corresponds to X12 as defined in the specification

<400>  8

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10          


<210>  9
<211>  12
<212>  PRT
<213>  artificial sequence

<220>
<223>  EGFR binding peptide

<400>  9

Tyr Arg Trp Tyr Gly Tyr Thr Pro Gln Asn Val Ile 
1               5                   10          


<210>  10
<211>  12
<212>  PRT
<213>  artificial sequence

<220>
<223>  EGFR binding peptide

<400>  10

Tyr Lys Trp Tyr Gly Tyr Thr Pro Gln Asn Val Ile 
1               5                   10          


<210>  11
<211>  13
<212>  PRT
<213>  artificial sequence

<220>
<223>  cell membrane potential distabilizing peptide

<400>  11

Phe Leu Lys Leu Leu Lys Lys Leu Ala Ala Lys Leu Phe 
1               5                   10              


<210>  12
<211>  20
<212>  PRT
<213>  artificial sequence

<220>
<223>  cell membrane lytic/nucleic acid binding peptide

<400>  12

Arg Leu Leu Arg Arg Leu Leu Arg Arg Leu Leu Arg Arg Leu Leu Arg 
1               5                   10                  15      


Arg Leu Leu Arg 
            20  


<210>  13
<211>  13
<212>  PRT
<213>  artificial sequence

<220>
<223>  cell membrane lytic/nucleic acid binding peptide

<400>  13

Arg Leu Leu Arg Arg Leu Leu Arg Arg Leu Leu Arg Lys 
1               5                   10              


<210>  14
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  EB(H2R)-lytic chimeric peptide; position 18, 21, 23, 24 and 28 
       are D-amino acids.

<400>  14

Tyr Arg Trp Tyr Gly Tyr Thr Pro Gln Asn Val Ile Gly Gly Gly Lys 
1               5                   10                  15      


Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys Lys 
            20                  25                  30          


<210>  15
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  HER2-lytic chimeric peptide; position 18, 21, 23, 24 and 28 are 
       D-amino acids.

<400>  15

Tyr Cys Asp Gly Phe Tyr Ala Cys Tyr Met Asp Val Gly Gly Gly Lys 
1               5                   10                  15      


Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys Lys 
            20                  25                  30          


<210>  16
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  VEGFR1-lytic chimeric peptide; position 18, 21, 23, 24 and 28 are
       D-amino acids.

<400>  16

Trp His Ser Asp Met Glu Trp Trp Tyr Leu Leu Gly Gly Gly Gly Lys 
1               5                   10                  15      


Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys Lys 
            20                  25                  30          


<210>  17
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  TfR-lytic chimeric peptide; position 18, 21, 23, 24 and 28 are 
       D-amino acids.

<400>  17

Thr His Arg Pro Pro Met Trp Ser Pro Val Trp Pro Gly Gly Gly Lys 
1               5                   10                  15      


Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys Lys 
            20                  25                  30          


<210>  18
<211>  33
<212>  PRT
<213>  artificial sequence

<220>
<223>  IL4-lyticL chimeric peptide

<400>  18

Lys Gln Leu Ile Arg Phe Leu Lys Arg Leu Asp Arg Asn Gly Gly Gly 
1               5                   10                  15      


Lys Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys 
            20                  25                  30          


Lys 
    


<210>  19
<211>  37
<212>  PRT
<213>  artificial sequence

<220>
<223>  IL13-lyticL chimeric peptide

<400>  19

Lys Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Gln Phe 
1               5                   10                  15      


Asn Gly Gly Gly Lys Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys 
            20                  25                  30          


Leu Leu Lys Lys Lys 
        35          


<210>  20
<211>  35
<212>  PRT
<213>  artificial sequence

<220>
<223>  Sema3A-lyticL chimeric peptide

<400>  20

Asn Tyr Gln Trp Val Pro Tyr Gln Gly Arg Val Pro Tyr Pro Arg Gly 
1               5                   10                  15      


Gly Gly Lys Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu 
            20                  25                  30          


Lys Lys Lys 
        35  


<210>  21
<211>  30
<212>  PRT
<213>  artificial sequence

<220>
<223>  EGFbuf sequence

<400>  21

Tyr His Trp Tyr Gly Tyr Thr Pro Gln Asn Val Ile Gly Gly Gly Gly 
1               5                   10                  15      


Gly Arg Leu Leu Arg Arg Leu Leu Arg Arg Leu Leu Arg Lys 
            20                  25                  30  


<210>  22
<211>  9
<212>  PRT
<213>  artificial sequence

<220>
<223>  IL11R binding peptide (cyclic peptide)

<400>  22

Cys Gly Arg Arg Ala Gly Gly Ser Cys 
1               5                   


<210>  23
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  TAT sequence

<400>  23

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1               5                   10      


<210>  24
<211>  11
<212>  PRT
<213>  artificial sequence

<220>
<223>  R11 sequence

<400>  24

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg 
1               5                   10      


<210>  25
<211>  28
<212>  PRT
<213>  artificial sequence

<220>
<223>  cytotoxic peptide

<400>  25

Arg Gln Ile Lys Ile Gln Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1               5                   10                  15      


Lys Ala Tyr Ala Arg Ile Gly Asn Ser Tyr Phe Lys 
            20                  25              


<210>  26
<211>  13
<212>  PRT
<213>  artificial sequence

<220>
<223>  IL4R binding peptide

<400>  26

Lys Gln Leu Ile Arg Phe Leu Lys Arg Leu Asp Arg Asn 
1               5                   10              


<210>  27
<211>  17
<212>  PRT
<213>  artificial sequence

<220>
<223>  cencer cell membrane lytic sequence; all amino acids are L-amino 
       acids

<400>  27

Lys Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys 
1               5                   10                  15      


Lys 
    


<210>  28
<211>  17
<212>  PRT
<213>  artificial sequence

<220>
<223>  IL13R binding peptide

<400>  28

Lys Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Gln Phe 
1               5                   10                  15      


Asn 
    


<210>  29
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  NRP1 binding peptide

<400>  29

Asn Tyr Gln Trp Val Pro Tyr Gln Gly Arg Val Pro Tyr Pro Arg 
1               5                   10                  15  


<210>  30
<211>  12
<212>  PRT
<213>  artificial sequence

<220>
<223>  HER2 binding pepitde

<400>  30

Tyr Cys Asp Gly Phe Tyr Ala Cys Tyr Met Asp Val 
1               5                   10          


<210>  31
<211>  12
<212>  PRT
<213>  artificial sequence

<220>
<223>  VEGFR1 binding pepitde

<400>  31

Trp His Ser Asp Met Glu Trp Trp Tyr Leu Leu Gly 
1               5                   10          


<210>  32
<211>  19
<212>  PRT
<213>  artificial sequence

<220>
<223>  VEGFR1 binding pepitde; -CONH2 is existing at C-terminal.

<400>  32

Val Glu Pro Asn Cys Asp Ile His Val Met Trp Glu Trp Glu Cys Phe 
1               5                   10                  15      


Glu Arg Leu 
            


<210>  33
<211>  19
<212>  PRT
<213>  artificial sequence

<220>
<223>  VEGFR1 binding pepitde

<400>  33

Gly Gly Asn Glu Cys Asp Ala Ile Arg Met Trp Glu Trp Glu Cys Phe 
1               5                   10                  15      


Glu Arg Leu 
            


<210>  34
<211>  12
<212>  PRT
<213>  artificial sequence

<220>
<223>  Transferrin Receptor(TfR) binding pepitde

<400>  34

Thr His Arg Pro Pro Met Trp Ser Pro Val Trp Pro 
1               5                   10          


<210>  35
<211>  9
<212>  PRT
<213>  artificial sequence

<220>
<223>  PSMA binding pepitde

<400>  35

Cys Gln Lys His His Asn Tyr Leu Cys 
1               5                   


<210>  36
<211>  7
<212>  PRT
<213>  artificial sequence

<220>
<223>  NRP1/VEGFR2 binding pepitde

<400>  36

Ala Thr Trp Leu Pro Pro Arg 
1               5           


<210>  37
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  EphB1R binding pepitde

<400>  37

Glu Trp Leu Ser 
1               


<210>  38
<211>  4
<212>  PRT
<213>  artificial sequence

<220>
<223>  EphB2R binding pepitde

<400>  38

Ser Asn Glu Trp 
1               


<210>  39
<211>  12
<212>  PRT
<213>  artificial sequence

<220>
<223>  GRP78 binding pepitde

<400>  39

Trp Asp Leu Ala Trp Met Phe Arg Leu Pro Val Gly 
1               5                   10          


<210>  40
<211>  13
<212>  PRT
<213>  artificial sequence

<220>
<223>  GRP78 binding pepitde (cyclic peptide)

<400>  40

Cys Thr Val Ala Leu Pro Gly Gly Tyr Val Arg Val Cys 
1               5                   10              


<210>  41
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  original lytic peptide; position 3, 6, 8, 9 and 13 are D-amino 
       acids, and -CONH2 is existing at C-terminal.

<400>  41

Leu Lys Leu Leu Lys Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu 
1               5                   10                  15  


<210>  42
<211>  30
<212>  PRT
<213>  artificial sequence

<220>
<223>  EB-original Lytic peptide; position 18, 21, 23, 24 and 28 are 
       D-amino acids, and -CONH2 is existing at C-terminal.

<400>  42

Tyr His Trp Tyr Gly Tyr Thr Pro Gln Asn Val Ile Gly Gly Gly Leu 
1               5                   10                  15      


Lys Leu Leu Lys Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu 
            20                  25                  30  


<210>  43
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  EB(H2R)-Lytic peptide; position 18, 21, 23, 24 and 28 are D-amino
       acids.

<400>  43

Tyr Arg Trp Tyr Gly Tyr Thr Pro Gln Asn Val Ile Gly Gly Gly Lys 
1               5                   10                  15      


Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys Lys 
            20                  25                  30          


<210>  44
<211>  33
<212>  PRT
<213>  artificial sequence

<220>
<223>  IL4-Lytic(D,L) peptide; position 19, 22, 24, 25 and 29 are 
       D-amino acids.

<400>  44

Lys Gln Leu Ile Arg Phe Leu Lys Arg Leu Asp Arg Asn Gly Gly Gly 
1               5                   10                  15      


Lys Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys 
            20                  25                  30          


Lys 
    


<210>  45
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  nLytic peptide; position 3, 7, 8 and 13 are D-amino acids.

<400>  45

Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Lys Leu Leu Lys Leu 
1               5                   10                  15  


<210>  46
<211>  32
<212>  PRT
<213>  artificial sequence

<220>
<223>  Sema3A(aa363-377)-nLytic peptide; position 20, 24, 25 and 30 are 
       D-amino acids.

<400>  46

Asn Tyr Gln Trp Val Pro Tyr Gln Gly Arg Val Pro Tyr Pro Arg Gly 
1               5                   10                  15      


Gly Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Lys Leu Leu Lys Leu 
            20                  25                  30          


<210>  47
<211>  24
<212>  PRT
<213>  artificial sequence

<220>
<223>  Sema3A(aa371-377)-nLytic; position 12, 16, 17 and 22 are D-amino 
       acids.

<400>  47

Gly Arg Val Pro Tyr Pro Arg Gly Gly Leu Leu Lys Leu Leu Lys Lys 
1               5                   10                  15      


Leu Leu Lys Lys Leu Leu Lys Leu 
            20                  


<210>  48
<211>  17
<212>  PRT
<213>  artificial sequence

<220>
<223>  cell membrane lytic peptide

<400>  48

Lys Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys 
1               5                   10                  15      


Lys 
    


<210>  49
<211>  17
<212>  PRT
<213>  artificial sequence

<220>
<223>  kLytic peptide; position 3, 6, 8, 9 and 13 are D-amino acids.

<400>  49

Lys Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys 
1               5                   10                  15      


Lys 
    


<210>  50
<211>  35
<212>  PRT
<213>  artificial sequence

<220>
<223>  Sema3A(363-377)-kLytic peptide; position 21, 24, 36, 27 and 31 
       are D-amino acids.

<400>  50

Asn Tyr Gln Trp Val Pro Tyr Gln Gly Arg Val Pro Tyr Pro Arg Gly 
1               5                   10                  15      


Gly Gly Lys Leu Leu Leu Lys Leu Leu Lys Lys Leu Leu Lys Leu Leu 
            20                  25                  30          


Lys Lys Lys 
        35  


<210>  51
<211>  27
<212>  PRT
<213>  artificial sequence

<220>
<223>  VEGFR2-Lytic peptide; position 13, 16, 18, 19 and 23 are D-amino 
       acids.

<400>  51

Ala Thr Trp Leu Pro Pro Arg Gly Gly Gly Lys Leu Leu Leu Lys Leu 
1               5                   10                  15      


Leu Lys Lys Leu Leu Lys Leu Leu Lys Lys Lys 
            20                  25          


<210>  52
<211>  12
<212>  PRT
<213>  artificial sequence

<220>
<223>  HER2 binding peptide

<400>  52

Leu Leu Gly Pro Tyr Glu Leu Trp Glu Leu Ser His 
1               5                   10          


<210>  53
<211>  15
<212>  PRT
<213>  artificial sequence

<220>
<223>  HER2 binding peptide

<400>  53

Ala Leu Val Arg Tyr Lys Asp Pro Leu Phe Val Trp Gly Phe Leu 
1               5                   10                  15  


<210>  54
<211>  6
<212>  PRT
<213>  artificial sequence

<220>
<223>  HER2 binding peptide

<400>  54

Lys Cys Cys Tyr Ser Leu 
1               5       


<210>  55
<211>  20
<212>  PRT
<213>  artificial sequence

<220>
<223>  HER2 binding peptide

<400>  55

Trp Thr Gly Trp Cys Leu Asn Pro Glu Glu Ser Thr Trp Gly Phe Cys 
1               5                   10                  15      


Thr Gly Ser Phe 
            20  


<210>  56
<211>  20
<212>  PRT
<213>  artificial sequence

<220>
<223>  HER2 binding peptide

<400>  56

Asp Thr Asp Met Cys Trp Trp Trp Ser Arg Glu Phe Gly Trp Glu Cys 
1               5                   10                  15      


Ala Gly Ala Gly 
            20  


<210>  57
<211>  86
<212>  PRT
<213>  Human immunodeficiency virus 1

<400>  57

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser 
1               5                   10                  15      


Gln Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe 
            20                  25                  30          


His Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly 
        35                  40                  45              


Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala His Gln Asn Ser Gln Thr 
    50                  55                  60                  


His Gln Ala Ser Leu Ser Lys Gln Pro Thr Ser Gln Pro Arg Gly Asp 
65                  70                  75                  80  


Pro Thr Gly Pro Lys Glu 
                85      


<210>  58
<211>  16
<212>  PRT
<213>  artificial sequence

<220>
<223>  Antp sequence

<400>  58

Arg Gln Ile Lys Ile Gln Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1               5                   10                  15      


<210>  59
<211>  12
<212>  PRT
<213>  artificial sequence

<220>
<223>  Hsp90 TPR binding peptide

<400>  59

Lys Ala Tyr Ala Arg Ile Gly Asn Ser Tyr Phe Lys 
1               5                   10          
